Pfizer, a publicly owned company headquartered in the United States, was founded in 1849, employs approximately 100,900 individuals, and reported $62.6B in revenue as of 2025. The company specializes in pharmaceutical manufacturing.
On July 31, Pfizer Inc. reported positive topline results from two phase 3 trials evaluating the efficacy and safety of Litfulo once daily in patients with active and stable nonsegmental vitiligo (NSV), across a broad range of disease severity. Earlier the same day, analysts at Erste Group Bank lifted their FY2027 EPS estimates for Pfizer. Concurrently, Pfizer filed for a label expansion in Japan for its congenital hemophilia therapy Hympavzi (marstacimab) to include children aged six to under 12 years. This followed the European Commission's authorization on July 29 of Pfizer and BioNTech’s updated COVID-19 vaccine for the 2026-2027 season. The vaccine targets the XFG variant, showing a strong immune response against contemporary circulating and emerging lineages, and is approved for individuals 6 months of age and older across all 27 European Union Member States plus Iceland, Liechtenstein, and Norway.
Subscribe for full access to Pfizer's products in full detail
Subscribe for full access to Pfizer's revenue in full detail
Subscribe for full access to Pfizer's products in full detail 
